[go: up one dir, main page]

RU95105449A - Пероральный препарат морфина с регулируемым выделением активного компонента - Google Patents

Пероральный препарат морфина с регулируемым выделением активного компонента

Info

Publication number
RU95105449A
RU95105449A RU95105449/14A RU95105449A RU95105449A RU 95105449 A RU95105449 A RU 95105449A RU 95105449/14 A RU95105449/14 A RU 95105449/14A RU 95105449 A RU95105449 A RU 95105449A RU 95105449 A RU95105449 A RU 95105449A
Authority
RU
Russia
Prior art keywords
morphine
preparation
oral preparation
active component
component releasing
Prior art date
Application number
RU95105449/14A
Other languages
English (en)
Other versions
RU2114613C1 (ru
Inventor
Перссон Кристиана
Se]
Ваксегорд Стаффан
Кулстад Серен
Фригрен Леннарт
Original Assignee
Гаселль Лабораториес АБ. (SE)
Гаселль Лабораториес АБ.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гаселль Лабораториес АБ. (SE), Гаселль Лабораториес АБ. filed Critical Гаселль Лабораториес АБ. (SE)
Publication of RU95105449A publication Critical patent/RU95105449A/ru
Application granted granted Critical
Publication of RU2114613C1 publication Critical patent/RU2114613C1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Изобретение относится к пероральному препарату морфина, имеющему полную биологическую доступность и, для растворения основного количества, нулевой порядок и независимо от рН выделение морфина в течение по меньшей мере 8 ч, предпочтительно по меньшей мере 12 ч, в течение которых растворяется меньше 100%. В препарате морфин в форме легкорастворимой соли находится в смеси с буферным агентом, и препарат покрыт диффузионной мембраной.

Claims (1)

  1. Изобретение относится к пероральному препарату морфина, имеющему полную биологическую доступность и, для растворения основного количества, нулевой порядок и независимо от рН выделение морфина в течение по меньшей мере 8 ч, предпочтительно по меньшей мере 12 ч, в течение которых растворяется меньше 100%. В препарате морфин в форме легкорастворимой соли находится в смеси с буферным агентом, и препарат покрыт диффузионной мембраной.
RU95105449A 1992-07-29 1993-07-28 Пероральный препарат морфина с регулируемым выделением активного компонента RU2114613C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9202250-8 1992-07-29
SE9202250A SE9202250D0 (sv) 1992-07-29 1992-07-29 Controlled release morphine preparation
PCT/SE1993/000642 WO1994003161A1 (en) 1992-07-29 1993-07-28 Controlled release morphine preparation

Publications (2)

Publication Number Publication Date
RU95105449A true RU95105449A (ru) 1997-06-10
RU2114613C1 RU2114613C1 (ru) 1998-07-10

Family

ID=20386851

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95105449A RU2114613C1 (ru) 1992-07-29 1993-07-28 Пероральный препарат морфина с регулируемым выделением активного компонента

Country Status (22)

Country Link
US (1) US5520931A (ru)
EP (1) EP0652747B1 (ru)
JP (2) JPH08501081A (ru)
KR (1) KR0156038B1 (ru)
CN (1) CN1053339C (ru)
AT (1) ATE176398T1 (ru)
AU (1) AU662239B2 (ru)
CA (1) CA2140254C (ru)
DE (1) DE69323428T2 (ru)
DK (1) DK0652747T3 (ru)
ES (1) ES2130278T3 (ru)
FI (1) FI950319A0 (ru)
GR (1) GR3030106T3 (ru)
HU (1) HU221683B1 (ru)
IL (1) IL106477A (ru)
NO (1) NO307407B1 (ru)
NZ (1) NZ254314A (ru)
PL (1) PL172571B1 (ru)
RU (1) RU2114613C1 (ru)
SE (1) SE9202250D0 (ru)
WO (1) WO1994003161A1 (ru)
ZA (1) ZA935488B (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
GB2284760B (en) * 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
GB2288117A (en) * 1994-03-01 1995-10-11 Euro Celtique Sa Sustained release morphine
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL109944A (en) † 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
PT888111E (pt) * 1996-03-08 2003-09-30 Nycomed Danmark As Composicao de multiplas unidades de dosagem de libertacao modificada.
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (ru) * 2001-05-02 2007-12-25 Euro Celtic S A Дозированная форма оксикодона и ее применение
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
CA2498798A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
WO2004041244A2 (en) * 2002-10-30 2004-05-21 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
RU2008113439A (ru) * 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
US8161977B2 (en) 2006-01-31 2012-04-24 Ethicon Endo-Surgery, Inc. Accessing data stored in a memory of a surgical instrument
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
US20080220064A1 (en) * 2006-12-06 2008-09-11 Ramesh Ketkar Anant Extended release matrix formulations of morphine
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
KR101492228B1 (ko) * 2007-07-26 2015-02-10 코와 가부시키가이샤 이브프로펜 및 트라넥사믹산 함유 고형제제
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
WO2018208241A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation and optimization of controlled release tablets of morphine sulphate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE295548C (ru) *
US4461598A (en) * 1982-02-08 1984-07-24 Flechs Ronald D Machine for installing drip irrigation conduit
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法

Also Published As

Publication number Publication date
SE9202250D0 (sv) 1992-07-29
FI950319A (fi) 1995-01-25
ATE176398T1 (de) 1999-02-15
PL172571B1 (pl) 1997-10-31
NO307407B1 (no) 2000-04-03
NO950318D0 (no) 1995-01-27
CN1053339C (zh) 2000-06-14
AU4595593A (en) 1994-03-03
EP0652747A1 (en) 1995-05-17
DK0652747T3 (da) 1999-09-20
ES2130278T3 (es) 1999-07-01
NO950318L (no) 1995-03-13
PL307262A1 (en) 1995-05-15
CA2140254C (en) 2004-01-20
CN1089472A (zh) 1994-07-20
US5520931A (en) 1996-05-28
GR3030106T3 (en) 1999-07-30
KR950702409A (ko) 1995-07-29
IL106477A (en) 1999-08-17
HUT71527A (en) 1995-12-28
FI950319A0 (fi) 1995-01-25
EP0652747B1 (en) 1999-02-03
DE69323428D1 (de) 1999-03-18
JP2006096771A (ja) 2006-04-13
HU9500260D0 (en) 1995-03-28
JPH08501081A (ja) 1996-02-06
HU221683B1 (hu) 2002-12-28
NZ254314A (en) 1996-09-25
RU2114613C1 (ru) 1998-07-10
DE69323428T2 (de) 1999-09-02
CA2140254A1 (en) 1994-02-17
KR0156038B1 (ko) 1998-11-16
IL106477A0 (en) 1993-11-15
ZA935488B (en) 1994-02-28
AU662239B2 (en) 1995-08-24
WO1994003161A1 (en) 1994-02-17
JP4976011B2 (ja) 2012-07-18

Similar Documents

Publication Publication Date Title
RU95105449A (ru) Пероральный препарат морфина с регулируемым выделением активного компонента
AU6770490A (en) Solid pharmaceutical compositions containing cimetidine
RU94035739A (ru) Фармацевтическая композиция, содержащая нифедипин, и способ ее получения
UA35569C2 (ru) Композиция для пролонгированного и контролируемого высвобождения пептидного лекарственного вещества и способ ее получения, способ приготовления суспензии для парентерального введения
CA2225286A1 (en) A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof
IE883810L (en) Sustained release pharmaceutical compositions
MY114388A (en) Multiple unit pharmaceutical preparation
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
CA2075876A1 (fr) Nouveaux derives d'arylethylamines, leurs procedes de preparation et lescompositions pharmaceutiques qui les contiennent
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
ATE63124T1 (de) Prodrugverbindungen, verfahren zu deren herstellung und diese enthaltende zubereitungen mit verzoegerter freisetzung.
EP0107209A1 (en) Sucralfate preparation
EP0173664A3 (en) Biologically active benzimidazole compounds and process for their preparation
NZ227990A (en) Cephemcarboxylic acid esters; pharmaceutical compositions and processes for preparation
DE60211486D1 (de) Verfahren zur herstellung einer schwimmfähigen tablette mit alfuzosin
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
FI955837A0 (fi) Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi
AU4304596A (en) A process for the preparation of substituted 4-ethyl-piperidines and an intermediate for the preparation of same
CA2015632A1 (en) Stable solutions of rebeccamycin analog and preparations thereof
AU607784B2 (en) Dry, rapidly soluble, compositions of beta-lactam antibiotics
CA2384301A1 (en) Sustained-release drug formulations for implantation
RU95105249A (ru) Гидрохлорид ng монометил-l-аргинина, способы его получения, способ получения фармацевтического препарата и способ лечения
EP0362908A3 (en) 1,4-dihydropyridine dicarboxylic acid derivatives
EP0335446A3 (en) Agents for treating neoplasms
JPS5659707A (en) Lasting antibiotic pharmaceutical and its preparation

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20070729